Latest posts

Zaf Qasim @resusone reviews the UKREBOA trial. No benefit shown, but is this really the end of REBOA in trauma? #FOAMed @stemlyns

Final day here at the Intensive Care Society State of the Art Congress, and although it's a shorter day there is still a huge amount of variety on the menu, so we're here to get started and get some knowledge. If you want to check out what we learnt on the previous two days, you can have a read of the day 1 blog here, and the day 2 blog here, so check those out and then come back for the finale, we'll wait.

We're back for the second day of the Intensive Care Society Sate of the Art Congress here in Birmingham! Yesterday was great and we learnt a lot with loads of things to think about for our own practice back home.

We love a jolly @StEmlyns and true to form we were off to the UK Intensive Care Society State of the Art conference this week in Birmingham. This is always a very impressive melting pot of clinical and academic experts in critical care, trauma and applied sciences.

Critical appraisal of the DEVICE trial as published in 2023 NEJM. VL outperforms DL in this study of critically unwell patients.

Critical Appraisal of the The PATCH trial of TXA Tranexamic Acid in major trauma patients.